Efficacy of metoclopramide in postoperative ileus after exploratory laparotomy
1Department of Pharmacy Practice, Wayne State University, Detroit, Michigan, USA.
Study Objective:
To assess the efficacy of metoclopramide for treatment of postoperative ileus in patients who underwent exploratory laparatomy.
Design:
Prospective observational study
Setting:
Surgical intensive care unit (SICU).
Patients:
Thirty-two patients who underwent exploratory laparatomy
Intervention:
Sixteen patients received metoclopramide, and 16 did not. The primary outcome was time to first postoperative bowel movement. Secondary end points were length of stay (LOS) in the SICU and total hospital LOS.
Measurements And Main Results:
The mean number of days to first bowel movement was nearly identical for both the treatment group and control group (4.8 vs 4.7 days, respectively, p=0.93). Length of stay in the SICU was 8.3 days for the treatment group and 8.6 days for the control group (p=0.89), and total LOS was 18.0 and 20.1 days, respectively (p=0.63).
Conclusion:
The time to first bowel movement was not significantly different between the treatment and control groups. Also, metoclopramide did not decrease LOS. Metoclopramide does not have a role in the treatment of postoperative ileus.
Related Concept Videos
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
